Get the Stockscreener App
0.53
4.83%
0.0244
After Hours:
.52
-0.01
-1.89%
Vistagen Therapeutics Inc stock is traded at $0.53, with a volume of 1.59M.
It is up +4.83% in the last 24 hours and down -20.16% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$0.5056
Open:
$0.5163
24h Volume:
1.59M
Relative Volume:
0.60
Market Cap:
$21.00M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-0.3948
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
-6.16%
1M Performance:
-20.16%
6M Performance:
-83.99%
1Y Performance:
-82.15%
1-Day Range:
$0.4903
$0.582
1-Week Range:
$0.43
$0.582
52-Week Range:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.53 | 20.03M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.32 | 124.83B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
793.53 | 84.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
843.55 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.61 | 41.70B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.86 | 38.30B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Downgrade | Maxim Group | Buy → Hold |
| Dec-17-25 | Downgrade | Stifel | Buy → Hold |
| Dec-17-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN - GlobeNewswire Inc.
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit - Financial Times
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Vistagen Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Holzer & Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action - marketscreener.com
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Vistagen - GlobeNewswire
VTGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - Nasdaq
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - GlobeNewswire
Technical Analysis: Will MSPRZ stock benefit from M AQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors with Losses ... - Black Hills Pioneer
Jobs Data: Is Vistagen Therapeutics Inc. stock a top pick in earnings seasonGold Moves & Reliable Intraday Trade Alerts - baoquankhu1.vn
Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis - Investing.com Nigeria
Will Vistagen Therapeutics Inc. stock reach all time highs in 2025Portfolio Gains Summary & Low Risk High Win Rate Stock Picks - mfd.ru
Vistagen advances PALISADE-4 trial with $61.8M in cash while refining placebo mitigation strategies - MSN
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Finding a voice: Inside Clearbrook’s PAL Program - AOL.com
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2026 Earnings Call Transcript - Insider Monkey
VTGN SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors ... - Bluefield Daily Telegraph
VTGN Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - marketscreener.com
High-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors - TipRanks
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - TMX Newsfile
Vistagen Therapeutics Balances Progress and Uncertainty - TipRanks
VTGN Investors with Large Losses Should Contact Robbins LLP - GlobeNewswire
VistaGen Therapeutics, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
2026-02-13 | VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlight - GuruFocus
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update - BioSpace
VistaGen (VTGN) Q3 2026 Earnings Call Transcript - The Globe and Mail
What is Vistagen Therapeutics Inc.’s valuation compared to sectorQuarterly Market Review & Long-Term Capital Growth Strategies - mfd.ru
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) - ACCESS Newswire
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates - Bitget
Vistagen (VTGN) Surpasses Revenue Expectations in Q3 - GuruFocus
Vistagen Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
R&D-driven loss at Vistagen (Nasdaq: VTGN) as PALISADE-4 Phase 3 advances - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesVTGN - PR Newswire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER - GlobeNewswire
The Gross Law Firm Notifies Vistagen Therapeutics, Inc. Investors of a Class Action Lawsuit and ... - Bluefield Daily Telegraph
The Gross Law Firm Notifies Vistagen Therapeutics, Inc. - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen - GlobeNewswire
Investors who lost money with shares of Vistagen Therapeutics, - openPR.com
VTGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - The Malaysian Reserve
LEVI & KORSINSKY, LLP ANNOUNCES SECURITIES CLASS ACTION FILED AGAINST VISTAGEN THERAPEUTICS UNDER FEDERAL SECURITIES LAWS - PR Newswire
Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2 - GuruFocus
Gap Down: Will Vistagen Therapeutics Inc outperform during market ralliesJuly 2025 Weekly Recap & Daily Momentum Trading Reports - baoquankhu1.vn
How Vistagen Therapeutics Inc. stock performs after earnings2025 Analyst Calls & Breakout Confirmation Alerts - mfd.ru
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Vistagen Therapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
2026-02-10 | VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Vistagen Therapeutics, Inc. to Contact the Firm Today! | NDAQ:VTGN | Press Release - Stockhouse
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):